Kisunla 350 mg, Konzentrat zur Herstellung einer Infusionslösung

7680695230017 CH-69523 Konzentrat

Associated product:

KISUNLA conc perf 350 mg 1 pce

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
23/02/2026
Patient information leaflet
Français
23/02/2026
Patient information leaflet
Italien
23/02/2026
Summary of Product Characteristics
Allemand
23/02/2026
Summary of Product Characteristics
Français
23/02/2026
Summary of Product Characteristics
Italien
23/02/2026

Detailed composition

Substance Quantity Type Category
donanemabum
350.0 MG Substance Wirkstoff (Principe actif)
natrii citras dihydricus
- Substance HNIDK
acidum citricum
- Substance HNIDK
saccharum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
11.5 MG Substance HBESI

Authorization holder

Eli Lilly (Suisse) SA

1214 Vernier

Authorization information

Swissmedic authorization number
69523
Drug name
Kisunla, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
N06DX05
Authorization status
Z
Dispensing category
A
First authorization
22/01/2026
Authorization expiration date
21/01/2031
IT Number
01.99.0.
Domain
Human medicine

Package details

Description (FR)
KISUNLA conc perf 350 mg 1 pce
Description (DE)
KISUNLA Konz Inf 350 mg 1 Stk
Market launch
25/02/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data